Kestra Medical raises FY27 revenue guidance to $141M after Q1 revenue up 60% to $31.0M

KESTRA MEDICAL TECHNOLOGIES, LTD.

F1Q27 revenue of $31.0M, up 60% YoY; gross margin expanded to 56.5% from 45.7%.
GAAP net loss widened to $44.1M from $25.8M; adjusted EBITDA loss was $24.0M vs $19.4M.
FY27 revenue guidance raised to $141M, representing 48% growth compared to FY26.
Cash and investments totaled $244.7M; total liquidity ~$320M including term-loan availability.
Growth driven by WCD market expansion, competitive share gains, new sales territories, and higher in-network mix.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.